December 7, 2009
5AM VENTURES RAISES $200M FOR 3RD LIFE SCIENCE VENTURE CAPITAL FUND

November 16, 2009
EMERGING DRUG DEVELOPER: FLEXION THERAPEUTICS - A RUTHLESS PURSUIT OF THE BOLD EXPERIMENT

November 9, 2009
WOMEN'S SEXUAL HEALTH COMPANY CHANGES NAME IN PREPARATION FOR MARKET ENTRY

October 16, 2009
FLEXION THERAPEUTICS RAISES $33 MILLION IN SERIES A FINANCING

October 15, 2009
KALOBIOS' KB001 ANTIBODY SHOWS ENCOURAGING SAFETY AND ACTIVITY IN NEW APPROACH TO FIGHTING PSEUDOMONAS INFECTION IN CYSTIC FIBROSIS PATIENTS

October 14, 2009
NEW DRUG DISCOVERY COMPANY ENVOY THERAPEUTICS RAISES $8 MILLION

October 7, 2009
RELYPSA INITIATES PHASE 2B CLINICAL TRIAL OF RLY5016 FOR THE PREVENTION OF HYPERKALEMIA IN HEART FAILURE PATIENTS

September 18, 2009
AMBRX STRIKES DEAL WITH WYETH (SOON-TO-BE PFIZER) TO MAKE ANTIBODY DRUGS

September 14, 2009
ACHAOGEN ANNOUNCES ACHN-490 CLINICAL DATA AT THE 49TH ANNUAL ICAAC MEETING

September 14, 2009
WILDCAT DISCOVERY TECHNOLOGIES SELECTED BY ALWAYSON AS A GOINGGREEN TOP 100 WINNER

August 25, 2009
ACHAOGEN APPOINTS JOHN C. DOYLE TO THE NEWLY CREATED POSITION OF CHIEF OPERATING OFFICER

August 10, 2009
IKARIA TO IN-LICENSE WORLDWIDE RIGHTS TO INVESTIGATIONAL PORTFOLIO FROM FIBREX MEDICAL

July 6, 2009
IKARIA TO IN-LICENSE BIOLINERX'S BL-1040

June 29, 2009
FIERCEBIOTECH NAMES ACHAOGEN AS ONE OF THE "FIERCE 15" BIOTECH COMPANIES OF 2009

June 12, 2009
FDA ACCEPTS FINAL SECTION OF NDA FILING FOR LUCASSIN®

June 1, 2009
ENTREMED PRESENTS RESULTS OF ENMD-2076 PHASE 1 STUDY IN ADVANCED CANCER PATIENTS

May 16, 2009
ACHAOGEN DATA SHOW RAPID RISE IN RATES OF RESISTANCE TO CURRENT ANTIBIOTICS; ILLUSTRATE GLOBAL NEED FOR NEW, WELL-TOLERATED AGENTS TO ADDRESS VARIED MECHANISMS OF RESISTANCE

May 13, 2009
SYNOSIA THERAPEUTICS BEGINS PHASE I TRIAL OF A NEW GENERATION TREATMENT FOR COGNITIVE IMPAIRMENT

May 1, 2009
PULMATRIX ANNOUNCES PH 1B/2A CLINICAL TRIAL OF NOVEL ICALM THERAPY FOR FLU

March 10, 2009
SYNOSIA ANNOUNCES SECOND AGREEMENT WITH ROCHE

March 9, 2009
IGENICA APPOINTS DR. MIKE ROTHE AS CEO AFTER CLOSING SERIES A FINANCING

March 3, 2009
ACHAOGEN SIGNS $26.6 MILLION CONTRACT WITH NIAID FOR DEVELOPMENT OF NEW THERAPY TO TREAT RESISTANT STRAINS OF NIAID CATEGORY A AND B PRIORITY PATHOGENS

February 24, 2009
PEARL THERAPEUTICS SECURES $8 MILLION IN DEBT FINANCING

February 9, 2009
BIOTECHS BEFRIEND NON-DILUTIVE FUNDS

February 9, 2009
ENTREMED PRESENTS INITIAL CLINICAL RESULTS FOR ENMD-2076

February 3, 2009
ACHAOGEN INITIATES PHASE 1 TRIAL OF ACHN-490 FOR TREATMENT OF MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS

January 8, 2009
ACHAOGEN RECEIVES ₤4.1 MILLION AWARD FROM THE WELLCOME TRUST TO ADVANCE ITS NEOGLYCOSIDES PORTFOLIO

January 7, 2009
ANAPHORE, INC. ANNOUNCES $25 MILLION SERIES A FINANCING

January 7, 2009
SYNOSIA THERAPEUTICS RAISES CHF32 MILLION IN SERIES B PRIVATE FINANCING